Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results
29 mars 2022 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum Appoints Rabia Gurses Ozden, M.D. and Soo J. Hong, M.B.A., to Board of Directors
17 mars 2022 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum Biotechnologies to Participate in the 42nd Annual Cowen Healthcare Conference
28 févr. 2022 08h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Appoints Richard Beckman M.D. as Chief Medical Officer
07 févr. 2022 16h05 HE
|
Adverum Biotechnologies, Inc.
- Dr. Beckman, a board-certified ophthalmologist, brings 30 years of experience in ophthalmology, drug development and retinal diseases including wet age-related macular degeneration - REDWOOD CITY,...
Adverum Biotechnologies Appoints Star Seyedkazemi, Pharm.D. as Chief Development Officer
06 janv. 2022 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy
04 janv. 2022 08h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022
21 déc. 2021 08h00 HE
|
Adverum Biotechnologies, Inc.
- Finalizing Two-Dose Study Design for Phase 2 Trial of ADVM-022 in Wet AMDwith Intention to Dose First Patient in Q32022 - - Anticipates Near-term Hires to Further Strengthen Executive Team - -...
Adverum Biotechnologies Appoints Rupert D’Souza, Ph.D., M.B.A. as Chief Financial Officer
06 déc. 2021 09h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Reports Third Quarter 2021 Results
04 nov. 2021 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting
09 oct. 2021 11h17 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Oct. 09, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...